We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
HOW DO WE EFFECTIVELY LOWER LDL-CHOLESTEROL IN HIGH-RISK PATIENTS?
- Authors
Soric, Razvan; Tărîţă, Victor; Silaghi, Patricia; Hategan, Anca; Pleşa, Vlad-Alexandru; Benedek, Theodora; Halatiu, Vasile-Bogdan
- Abstract
Background: In patients who underwent percutaneous coronary intervention for acute coronary syndrome (ACS) the low-density lipoprotein (LDL) cholesterol target is below 55 mg/dL. Reaching this target is almost impossible to achieve with high-dose statin treatment in monotherapy. Objective: The purpose of the present study is to evaluate lipid-lowering therapy thus comparing statin monotherapy from statin with ezetimibe therapy in patients following an ACS. Material and methods: The study includes 60 consecutive patients admitted to the Cardiology Department of the Emergency Clinical County Hospital Târgu Mureş with ACS. Patients were randomly assigned to one of the two treatment groups: Group 1 - high-dose statin and Group 2 - high-dose statin + ezetimibe 10 mg. For all patients, the lipid profile was assessed upon admission and after one month of treatment. Results : The mean age of patients in Group 1 was 61.10 ± 11.22 years while in Group 2 it was 61.73 ± 14.22 years (p= 0.84). Upon admission, all patients had an LDL-cholesterol above the target value of 55 mg/dL and there was no significant difference in lipids at baseline between the two groups (all p > 0.05). After one month of lipid-lowering treatment, the patients in Group 2 (40.71 ± 15.90 mg/dL) presented a significantly lower value of LDL-cholesterol compared to the patients in Group 1 (70.89 ± 20.16 mg/dL) with p= 0.002. The high-dose statin + ezetimibe had a significantly higher reduction effect on LDL-cholesterol in one month of treatment compared to high-dose statin monotherapy (-69.40% versus -40.54%; p= 0.006). Conclusions: The current study's findings show that high-dose statin + ezetimibe is more effective in lowering LDL cholesterol and reaching targets faster in high-risk patients than high-dose statin monotherapy. This opens a new paradigm in secondary prevention and consequently it shows a significant decrease in the risk of a recurrent major cardiovascular event.
- Subjects
ROMANIA; HYPERCHOLESTEREMIA prevention; COMBINATION drug therapy; LDL cholesterol; CONFERENCES &; conventions; EZETIMIBE; ACUTE coronary syndrome; STATINS (Cardiovascular agents); PERCUTANEOUS coronary intervention; DRUG efficacy
- Publication
Acta Marisiensis. Seria Medica, 2024, Vol 70, p29
- ISSN
2668-7755
- Publication type
Article